Centre Antoine Lacassagne

Running trials

• Not yet recruiting

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Centre Oscar Lambret· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

  NCT07234877· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Not yet recruiting

  Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer

  NCT07857486· Phase 2· Institut Paoli-Calmettes· Source

• Not yet recruiting

  Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

  NCT07847398· Centre Antoine Lacassagne· Source

• Not yet recruiting

  Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

  NCT07633613· Phase 4· Centre Antoine Lacassagne· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· UNICANCER· Source

• Not yet recruiting

  Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

  NCT07340619· Phase 2· UNICANCER· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

  NCT07429487· Centre Antoine Lacassagne· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

  NCT07473128· Phase 3· Pharmacosmos A/S· Source

• Not yet recruiting

  Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer

  2026-526319-12-00· Phase 3· Unicancer· Source

• Recruiting

  Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

  NCT07360743· Phase 2· UNICANCER· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.

  2025-521437-88-00· Phase 2· Groupe Oncologie Radiotherapie Tete Cou· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Not yet recruiting

  MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

  2025-522058-38-00· Phase 2· Centre Leon Berard· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

  NCT07193394· Phase 2· Institut Curie· Source

• Recruiting

  Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

  NCT06908993· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· Phase 1/2· AstraZeneca· Source

• Recruiting

  Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

  NCT07563205· GFPC Investigation· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE2

  2024-517018-14-00· Phase 2· Institut Gustave Roussy· Source

• Recruiting

  Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  2025-520555-89-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· AbbVie· Source

• Recruiting

  Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

  NCT07192068· Phase 2· UNICANCER· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

  NCT06959108· Phase 2· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

  NCT06529718· Phase 2· UNICANCER· Source

• Recruiting

  Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

  NCT07028125· Phase 4· Centre Francois Baclesse· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  Biomedical Innovation for Facial Bone Reconstruction in Oncology: BIOFACE PASS a Medico-economic Study Describing the Standard Pathway of Patients Treated by Free Bone Flap

  NCT06771336· University Hospital, Toulouse· Source

Showing 50 of 251.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer36 recruiting
• Metastatic breast cancer18 recruiting
• Head and neck cancer15 recruiting
• Colorectal cancer14 recruiting
• Ovarian cancer13 recruiting
• Prostate cancer11 recruiting
• Bladder cancer10 recruiting
• Endometrial cancer8 recruiting
• Kidney cancer8 recruiting
• Childhood cancers7 recruiting
• Pancreatic cancer7 recruiting
• Sarcoma6 recruiting
• Triple-negative breast cancer6 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Acute myeloid leukaemia3 recruiting
• Liver and biliary tract cancer3 recruiting
• Neuroendocrine tumours3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Cervical cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Melanoma2 recruiting
• Meningioma2 recruiting
• Glioblastoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroblastoma1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Completed

  A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

  NCT04892017· Phase 1/2· Deciphera Pharmaceuticals Inc.· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Evaluation of the Medical Service by Socio-aesthetics in Oncology

  NCT06035731· Centre Hospitalier de Valence· Source

• Recruiting

  Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

  NCT06247826· Groupe Francais De Pneumo-Cancerologie· Source

• Completed

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source

• Completed

  Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck

  2023-503270-20-00· Phase 1· Groupe Oncologie Radiotherapie Tete Cou· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· UNICANCER· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Unicancer· Source

• Completed

  A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene

  NCT05469178· Phase 1/2· Bergenbio ASA· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· BeiGene· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK)

  NCT05551117· Phase 2· Macrogenics Inc.· Source

• Completed

  Conventional Oxygen Therapy Versus Continuous Transnasal High Flow Oxygen Therapy for Head and Neck Diagnostic Panendoscopy Under General Anesthesia in Spontaneous Ventilation

  NCT05696288· Centre Antoine Lacassagne· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Amgen Inc.· Source

• Recruiting

  TARGETed Therapy Drug MONITOring in DIGestive Oncology

  NCT05443087· UNICANCER· Source

• Terminated

  A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

  NCT05389462· Phase 1· ADC Therapeutics S.A.· Source

• Active, not recruiting

  Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

  NCT05257408· Phase 3· Corcept Therapeutics· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· SOTIO Biotech AG· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source

• Completed

  Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

  NCT04992949· Phase 2· French Innovative Leukemia Organisation· Source

• Completed

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

  NCT05486182· Phase 4· GE Healthcare· Source

• Completed

  Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

  NCT05070208· Acute Leukemia French Association· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC

  NCT04725396· UNICANCER· Source

• Recruiting

  A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

  NCT04641247· Phase 2· GlaxoSmithKline· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Daiichi Sankyo· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· Phase 3· Mirati Therapeutics Inc.· Source

• Terminated

  Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

  NCT04450836· Phase 2· UNICANCER· Source

• Active, not recruiting

  RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

  NCT04597125· Phase 4· Bayer· Source

• Completed

  Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

  NCT04357873· Phase 2· UNICANCER· Source

• Completed

  A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts

  2024-518506-41-00· Phase 1/2· Promontory Therapeutics Inc.· Source

• Terminated

  Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

  NCT04826198· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source

• Completed

  Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.

  NCT04367779· Centre Leon Berard· Source

• Active, not recruiting

  Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

  NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  NCT04300556· Phase 1/2· Eisai Inc.· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Taiho Oncology, Inc.· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)

  NCT04728113· Institut Curie· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

  NCT04132960· Phase 2· UNICANCER· Source

Showing 50 of 97.

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer16 works · 37 trials